Matches in DBpedia 2014 for { ?s ?p Oseltamivir INN /ɒsəlˈtæmɨvɪər/, marketed under the trade name Tamiflu, is an antiviral licensed to prevent or slow the spread of influenza A and influenza B (flu) virus between cells in the body by stopping the virus from chemically cutting ties with its host cell. The drug is taken orally in capsules or as a suspension. Oseltamivir is a prodrug, a (relatively) inactive chemical, which is converted into its active form by metabolic process after it is taken into the body. It was the first orally active neuraminidase inhibitor commercially developed. It was developed by C.U. Kim, W. Lew, and X. Chen of US-based Gilead Sciences, and is marketed by Genentech. Gilead licensed the exclusive rights to Roche in 1996. The starting material of the Tamiflu production process is shikimic acid. It is extracted from the pods of the Chinese star anise, grown in mountain provinces in the south west of China.Oseltamivir's benefits in those who are otherwise healthy do not appear to outweigh its risks. No benefit of treatment, on hospitalization or risk of death has been found in randomized trials in those people at high risk for complications or the elderly. The United States Centers for Disease Control continues to recommend the use of oseltamavir treatment for people at high risk for complications and the elderly and those at lower risk who present within 48 hours of first symptoms of infection. Prior to 2013, oseltamivir's effectiveness was debated as its manufacturer, Roche, originally refused to release the data from all of its trials for independent analysis. Together, these published studies suggest that oseltamivir reduces the duration of symptoms by 0.5–1 day. It is unclear whether this medication affects transmission of influenza in adults. Any benefit of treatment must be balanced against side effects, which include psychiatric symptoms and increased rates of vomiting.As of December 15, 2010, the World Health Organization (WHO) reported 314 samples of the prevalent 2009 pandemic H1N1 flu tested worldwide have shown resistance to oseltamivir. However, the predominant strains of both influenza A and influenza B active during the 2012-2013 flu season in the US are sensitive to oseltamivir. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Oseltamivir abstract "Oseltamivir INN /ɒsəlˈtæmɨvɪər/, marketed under the trade name Tamiflu, is an antiviral licensed to prevent or slow the spread of influenza A and influenza B (flu) virus between cells in the body by stopping the virus from chemically cutting ties with its host cell. The drug is taken orally in capsules or as a suspension. Oseltamivir is a prodrug, a (relatively) inactive chemical, which is converted into its active form by metabolic process after it is taken into the body. It was the first orally active neuraminidase inhibitor commercially developed. It was developed by C.U. Kim, W. Lew, and X. Chen of US-based Gilead Sciences, and is marketed by Genentech. Gilead licensed the exclusive rights to Roche in 1996. The starting material of the Tamiflu production process is shikimic acid. It is extracted from the pods of the Chinese star anise, grown in mountain provinces in the south west of China.Oseltamivir's benefits in those who are otherwise healthy do not appear to outweigh its risks. No benefit of treatment, on hospitalization or risk of death has been found in randomized trials in those people at high risk for complications or the elderly. The United States Centers for Disease Control continues to recommend the use of oseltamavir treatment for people at high risk for complications and the elderly and those at lower risk who present within 48 hours of first symptoms of infection. Prior to 2013, oseltamivir's effectiveness was debated as its manufacturer, Roche, originally refused to release the data from all of its trials for independent analysis. Together, these published studies suggest that oseltamivir reduces the duration of symptoms by 0.5–1 day. It is unclear whether this medication affects transmission of influenza in adults. Any benefit of treatment must be balanced against side effects, which include psychiatric symptoms and increased rates of vomiting.As of December 15, 2010, the World Health Organization (WHO) reported 314 samples of the prevalent 2009 pandemic H1N1 flu tested worldwide have shown resistance to oseltamivir. However, the predominant strains of both influenza A and influenza B active during the 2012-2013 flu season in the US are sensitive to oseltamivir. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.".